Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Colin P Dinney

Showing results (61-70 of 202) with videos related to

Pageof 21
Sort By:
Human Pathology|May 16, 2018
Small cell carcinoma of the urinary bladder: a clinicopathological and immunohistochemical analysis of 81 casesGang Wang, Li Xiao, Miao Zhang, et al.
European Urology|February 29, 2016
Papillary Recurrence of Bladder Cancer at First Evaluation after Induction Bacillus Calmette-Guérin Therapy: Implication for Clinical Trial DesignChinedu O Mmeje, Charles C Guo, Jay B Shah, et al.
BJU International|December 2, 2021
Should patients with non-muscle-invasive bladder cancer discontinue fibrin clot inhibitors during bacille Calmette-Guérin?Niyati Lobo, Patrick J Hensley, Kelly K Bree, et al.
Cancer|June 24, 2010
A multiplexed, particle-based flow cytometric assay identified plasma matrix metalloproteinase-7 to be associated with cancer-related death among patients with bladder cancerRobert S Svatek, Jay B Shah, Jinliang Xing, et al.
Cancer Prevention Research (Philadelphia, Pa.)|April 22, 2015
Mitochondrial DNA Content as Risk Factor for Bladder Cancer and Its Association with Mitochondrial DNA PolymorphismsStephen B Williams, Yuanqing Ye, Maosheng Huang, et al.
Urology|September 19, 2006
Clinical model of lifetime cost of treating bladder cancer and associated complicationsElenir B C Avritscher, Catherine D Cooksley, H Barton Grossman, et al.
The Journal of Urology|October 16, 2007
Differences in survival among patients with sarcomatoid carcinoma, carcinosarcoma and urothelial carcinoma of the bladderJonathan L Wright, Peter C Black, Gordon A Brown, et al.
American Journal of Clinical Pathology|November 13, 2014
Uroplakin II is a more sensitive immunohistochemical marker than uroplakin III in urothelial carcinoma and its variantsWenping Li, Yu Liang, Michael T Deavers, et al.
International Journal of Cancer|December 14, 2017
Dietary patterns and risk of recurrence and progression in non-muscle-invasive bladder cancerEllen Westhoff, Xifeng Wu, Lambertus A Kiemeney, et al.
Medicine|August 7, 2016
Comparison between whole mount tissue preparations and virtual tissue microarray samples for measuring Ki-67 and apoptosis indices in human bladder cancer: A cross-sectional studyHisashi Oshiro, Bogdan A Czerniak, Kentaro Sakamaki, et al.
Pageof 21

Showing results (61-70 of 202) with videos related to

Sort By:
Pageof 21
Human Pathology|May 16, 2018
Small cell carcinoma of the urinary bladder: a clinicopathological and immunohistochemical analysis of 81 casesGang Wang, Li Xiao, Miao Zhang, et al.
European Urology|February 29, 2016
Papillary Recurrence of Bladder Cancer at First Evaluation after Induction Bacillus Calmette-Guérin Therapy: Implication for Clinical Trial DesignChinedu O Mmeje, Charles C Guo, Jay B Shah, et al.
BJU International|December 2, 2021
Should patients with non-muscle-invasive bladder cancer discontinue fibrin clot inhibitors during bacille Calmette-Guérin?Niyati Lobo, Patrick J Hensley, Kelly K Bree, et al.
Cancer|June 24, 2010
A multiplexed, particle-based flow cytometric assay identified plasma matrix metalloproteinase-7 to be associated with cancer-related death among patients with bladder cancerRobert S Svatek, Jay B Shah, Jinliang Xing, et al.
Cancer Prevention Research (Philadelphia, Pa.)|April 22, 2015
Mitochondrial DNA Content as Risk Factor for Bladder Cancer and Its Association with Mitochondrial DNA PolymorphismsStephen B Williams, Yuanqing Ye, Maosheng Huang, et al.
Urology|September 19, 2006
Clinical model of lifetime cost of treating bladder cancer and associated complicationsElenir B C Avritscher, Catherine D Cooksley, H Barton Grossman, et al.
The Journal of Urology|October 16, 2007
Differences in survival among patients with sarcomatoid carcinoma, carcinosarcoma and urothelial carcinoma of the bladderJonathan L Wright, Peter C Black, Gordon A Brown, et al.
American Journal of Clinical Pathology|November 13, 2014
Uroplakin II is a more sensitive immunohistochemical marker than uroplakin III in urothelial carcinoma and its variantsWenping Li, Yu Liang, Michael T Deavers, et al.
International Journal of Cancer|December 14, 2017
Dietary patterns and risk of recurrence and progression in non-muscle-invasive bladder cancerEllen Westhoff, Xifeng Wu, Lambertus A Kiemeney, et al.
Medicine|August 7, 2016
Comparison between whole mount tissue preparations and virtual tissue microarray samples for measuring Ki-67 and apoptosis indices in human bladder cancer: A cross-sectional studyHisashi Oshiro, Bogdan A Czerniak, Kentaro Sakamaki, et al.
Pageof 21